Symprove Ltd’s Post

Even after decades of Antibiotic use as a growth promoter, and industry acceptance of its anti-inflammatory effects, we still do not fully comprehend the mode of action of AGPs. This knowledge is key for the current AGP free times and the search for options to replace antibiotics. During my Ph.D., we tried to understand better the effects of AGP on intestinal immune system, and I am happy to share the article we published based on this research! Main findings: -The present study demonstrated that the use of bacitracin as an AGP modulates the small intestine immune system, especially in the first phase of the broiler’s life (up to 14 days). -Broilers with BMD supplementation were found to have a lower production of IL-16, IFN-γ, M-CSF, IL-21, MIP-1β and VEGF in the jejunum at 14 d. BMD reduced CCL-5 concentration in the jejunum at D36. -In the ileum, BMD-supplemented broilers showed a reduced IL-6 production level. At day 36, BMD reduced IL-16 and MIP-3α production but increased VEGF concentration in the ileum tissue. -BMD anti-inflammatory effects include not only innate immunity but also s adaptive immune response as seen by the decreased production of IL-21 and IL-16. Special acknowledgment to my advisors Michael Kogut and Yuhua Farnell, and my colleagues Cristiano Bortoluzzi, Annah Lee, Ph.D., MPH for the help on this publication! https://lnkd.in/gAEje4MZ

Hi everyone! I've published my latest article on Substack, which explores the inspiring story of Steffanie Strathdee, a scientist who embarked on a quest to save her dying husband using phages, which are viruses that infect and destroy bacteria. Her journey not only illustrates the importance of love and resilience in trying times, but also shines a spotlight on the power of collaboration between scientific communities, especially while researching new and obscure medical techniques. Do have a look at the article - Strathdee’s success with phage therapy could be replicated to tackle antibiotic resistance, which is becoming a major issue due to the overuse of antibiotics in healthcare and agriculture. Here is the link to the article: https://lnkd.in/e-zf78kb #phages #antibiotics #healthcare #pharmacology

The impact of antibiotics on the gut microbiota of children recovering from watery diarrhoea. https://lnkd.in/dQ2_x6j3 NATURE Son-Nam H. Le, Chau Nguyen Ngoc Minh, Paola Florez de Sessions, Song Jie, Chau Tran Thi Hong, Guy Thwaites, Stephen Baker, Duy Thanh Pham & Hao Chung-The (Oxford University Clinical Research Unit) The findings demonstrate that antibiotic treatment slows gut microbiota recovery in children following watery diarrhoea. #microbiome #antibiotics #gutmicrobiota #diarrhoea #infectiousdisease

📢 #Plant-Derived Products with Therapeutic Potential against #Gastrointestinal Bacteria 👨🎓 by Fatimah I. Qassadi, Zheying Zhu, and Tanya Monaghan 🔗 Full article: https://lnkd.in/g3gg6RJE The rising burden of #antimicrobialresistance and increasing infectious disease outbreaks, including the recent COVID-19 pandemic, has led to a growing demand for the development of natural products as a valuable source of leading medicinal compounds. There is a wide variety of active constituents found in plants, making them an excellent source of antimicrobial agents with therapeutic potential as alternatives or potentiators of antibiotics. The structural diversity of phytochemicals enables them to act through a variety of mechanisms, targeting multiple biochemical pathways, in contrast to traditional antimicrobials. Moreover, the bioactivity of the herbal extracts can be explained by various metabolites working in synergism, where hundreds to thousands of metabolites make up the extract. Although a vast amount of literature is available regarding the use of these herbal extracts against bacterial and viral infections, critical assessments of their quality are lacking. This review aims to explore the efficacy and antimicrobial effects of herbal extracts against clinically relevant gastrointestinal infections including pathogenic Escherichia coli, toxigenic Clostridioides difficile, Campylobacter and Salmonella species. The review will discuss research gaps and propose future approaches to the translational development of plant-derived products for drug discovery purposes for the treatment and prevention of gastrointestinal infectious diseases.

Resistant E. Coli Rises Despite Drop in Ciprofloxacin Use After a nearly threefold drop in prescriptions for the antibiotic ciprofloxacin between 2015 and 2021, the rates of ciprofloxacin-resistant E. coli bacteria circulating in the community did not decline. In fact, a study of Seattle-area women over age 50 who had not taken any antibiotics for at least a year discovered that the incidence of gut-colonizing ciprofloxacin-resistant E. coli actually increased. About 1 in 5 women in the study were affected. The results are consistent with theoretical models indicating that, once a drug-resistant form of E.coli emerges, it will continue to spread by taking up long-term residence in individuals' gut microbiomes. https://lnkd.in/gf-qhU8N #aspenalert #biotech #bioprocess

Hii connections 😇 I'm going to be share about my article on PENICILLIN peniciln is one of the first and still one of the most widely used antibiotic agents, derived from the Penicillium mold. In 1928 Scottish bacteriologist Alexander Fleming first observed that colonies of the bacterium Staphylococcus aureus failed to grow in those areas of a culture that had been accidentally contaminated by the green mold Penicillium notatum. He isolated the mold, grew it in a fluid medium, and found that it produced a substance capable of killing many of the common bacteria that infect humans. Australian pathologist Howard Florey and British biochemist Ernst Boris Chain isolated and purified penicillin in the late 1930s, and by 1941 an injectable form of the drug was available for therapeutic use. The several kinds of penicillin synthesized by various species of the mold Penicillium may be divided into two classes: the naturally occurring penicillins (those formed during the process of mold fermentation) and the semisynthetic penicillins (those in which the structure of a chemical substance—6-aminopenicillanic acid—found in all penicillins is altered in various ways). Because it is possible to change the characteristics of the antibiotic, different types of penicillin are produced for different therapeutic purposes. Penicillins are used in the treatment of throat infections, meningitis, syphilis, and various other infections. The chief side effects of penicillin are hypersensitivity reactions, including skin rash, hives, swelling, and anaphylaxis, or allergic shock. The more serious reactions are uncommon. Milder symptoms may be treated with corticosteroids but usually are prevented by switching to alternative antibiotics. Anaphylactic shock, which can occur in previously sensitized individuals within seconds or minutes, may require immediate administration of epinephrine. #snsinstitutions #snsdesignthinkers #designthinking

Our viewpoint article ‘Is this pill an antibiotic or a painkiller? Improving the identification of oral antibiotics for better use’ is now available online! 📢 📄 ·        There is a large variation in names that people use to refer to antibiotics and these often relate to their physical appearance while antibiotics come in many different physical presentations 💊 ·        We propose to use physical appearance tools to improve the identification of oral generic antibiotics and distinction from other commonly sold medicines (such as painkillers) 👁  ·        Improving antibiotic identification can help nudge awareness about antibiotics and their responsible use ✅ ·        Global initiatives to improve responsible antibiotic use will not work optimally if the medicine cannot be recognised easily and linked to public health messages 🔗 I am very grateful to be part of this great consortium with colleagues around the globe! 🌍 🌏 Heiman Wertheim; Samuel Afari-Asiedu; Kwaku Poku Asante; Paul Newton; Proochista Ariana; Céline Caillet; Rogier van Doorn; Wasif Khan; MD Matin; Chibuzor Uchea, PhD; Jude Nwokike; Wellcome Trust https://lnkd.in/eNGMK5-C

Another thoughtful paper from the lab of Alex Mira, Bob Rosier and colleagues at the Fisabio foundation in Valencia reinforcing the prebiotic benefit of topical nitrate. Danuta Mazurel et al report that the addition of nitrate decreased dysbiosis in an in vitro biofilm assay consisting of plaque derived from periodontal patients. Most striking was a decrease in Porphyromonas gingivalis and Treponema maltophilum -- both associated with periodontitis -- among other pathogenic-associated species. Topical nitrate likely reduced biofilm growth of diseases-associated bacteria through the antimicrobial properties of nitrate-nitrite reduction to nitric oxide. Mazurel et al observations are consistent with previous findings showing nitrate shifts the saliva community of pathogenic-associated bacteria towards periodontal health-associated, nitric oxide-promoting, Rothia and Neisseria. Healthy mouth, healthy heart. It may be worthwhile to track your salivary prebiotic nitrate with MyFitStrip's pH and Prebiotic Nitric Oxide Saliva Test Strips. #testing #dentalcare #periodontaldisease #cardiovascular #oralhealth #nitricoxide #oralhygiene #microbiome #infectiousdiseases #diseaseprevention #healthcare #health #consumerbehavior #prebiotics #gumdisease #alzheimersdisease #atherosclerosis

We are happy to announce that data from the successful phase 3 study ERADICATE were published in the #NewEnglandJournalofMedicine (NEJM), one of the world's leading peer-reviewed medical journals. 🏥 In the #study, Basilea’s #antibiotic #ceftobiprole, was evaluated for the treatment of bacterial bloodstream infections caused by 𝘚𝘵𝘢𝘱𝘩𝘺𝘭𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘢𝘶𝘳𝘦𝘶𝘴 bacteria, also known as 𝘚𝘵𝘢𝘱𝘩𝘺𝘭𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘢𝘶𝘳𝘦𝘶𝘴 bacteremia (#SAB) in adult patients. Ceftobiprole showed similar clinical benefit compared to daptomycin, which is a standard of care antibiotic in the treatment of SAB. 💬 Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: "Based on ERADICATE and additional randomized controlled phase 3 studies, we have recently submitted a New Drug Application to the US Food and Drug Administration, seeking approval of ceftobiprole for treating patients in three indications: 𝘚𝘵𝘢𝘱𝘩𝘺𝘭𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘢𝘶𝘳𝘦𝘶𝘴 bacteremia, including right-sided infective endocarditis, acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia." 🔗 Basilea press release: https://lnkd.in/edDe_jr4 📰 Online publication in the New England Journal of Medicine: https://lnkd.in/eSdPWXU7